Related Experiment Video
Updated: Jul 9, 2026

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
Published on: September 19, 2019
HME as a transformative platform in pharmaceutics: from molecular dispersion engineering to personalized drug
Siva S Kolipaka1, Atabak Ghanizadeh Tabriz2, Vivek Garg3
1Centre for Research Innovation (CRI), University of Greenwich, Chatham ME4 4TB, UK.
None:
Hot melt extrusion (HME) has become a major continuous manufacturing approach for producing amorphous solid dispersions (ASDs) that address the poor solubility and limited bioavailability of many contemporary drug candidates. Through controlled application of heat and mechanical shear, HME enables uniform molecular dispersion of the drug within a polymer carrier, converting crystalline APIs into kinetically stable amorphous systems with improved dissolution profiles and enhanced supersaturation. The performance of these extrudates is determined by essential Critical Quality Attributes (CQAs) such as glass transition temperature (Tg), residual crystallinity, dissolution behaviour and impurity levels which in turn depend on Critical Material Attributes (CMAs) including polymer properties, drug loading, hygroscopicity and particle size, as well as Critical Process Parameters (CPPs) like screw speed, barrel temperature, residence time and specific mechanical energy (SME). A Quality by Design (QbD) framework provides a structured basis for formulation and process optimization by mapping the relationships between CQAs, CMAs and CPPs to establish a robust design space. Modern implementation strategies increasingly incorporate Process Analytical Technology (PAT) tools and real-time release testing (RTRT), allowing continuous monitoring of amorphization, mixing efficiency and chemical stability in alignment with FDA, EMA, and ICH regulatory expectations. Emerging case studies highlight the broad applicability of HME beyond traditional bioavailability enhancement, with successful use in taste-masked paediatric formulations, abuse-deterrent platforms, fixed-dose combinations (FDCs), and gastro-retentive systems. Together, these developments reinforce HME as a mature, solvent-free, and industrially scalable technology for manufacturing advanced oral drug products with consistently high performance and improved patient outcomes.
More Related Videos
08:26Dissolving Microneedle Array Patches Manufactured By Solvent Casting Technique and Essential Characterization of Microneedle-Based Biomedical Devices
Published on: January 30, 2026
07:32Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles
Published on: August 28, 2015
Related Concept Videos
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Modified-Release Drug Delivery Systems: Site-Targeted
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Oral Drug Delivery Systems: Introduction
Drug Delivery Systems: Different Types
Modified-Release Drug Delivery Systems: Rate-Programmed II